Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 2/20 | 0.40 |
| ▸ | NPY2R | P49146 | 2/20 | 0.40 |
| ▸ | NPY4R | P50391 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.39 |
| ▸ | RXFP4 | Q8TDU9 | 1/20 | 0.39 |
| ▸ | RXFP3 | Q9NSD7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086892 | 1.00 | NPY1R (0.40) | NPY1RNPY2RNPY4RNPY5RRXFP1 | |
| SCHEMBL4082293 | 0.96 | NPY4R (0.41) | NPY1RNPY2RNPY4RNPY5RENPEP | |
| SCHEMBL4082284 | 0.96 | NPY4R (0.41) | NPY1RNPY2RNPY4RNPY5RENPEP | |
| SCHEMBL31757511 | 0.92 | RXFP1 (0.46) | NPY1RNPY2RNPY4RNPY5RRXFP1 | |
| SCHEMBL4092981 | 0.92 | NPY4R (0.48) | NPY1RNPY2RNPY4RNPY5RRXFP1 | |
| SCHEMBL4092974 | 0.92 | NPY4R (0.48) | NPY1RNPY2RNPY4RNPY5RRXFP1 | |
| SCHEMBL4093294 | 0.91 | OPRM1 (0.46) | — | |
| SCHEMBL4093290 | 0.91 | OPRM1 (0.46) | — | |
| SCHEMBL27745761 | 0.91 | ENPEP (0.45) | NPY1RNPY2RNPY4RNPY5RENPEP | |
| SCHEMBL30518992 | 0.90 | RXFP1 (0.46) | NPY1RNPY2RNPY4RNPY5RRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | NPY1R 2090/4885NPY2R 2145/4885NPY4R 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.